MingMed Biotechnology Co., Ltd. is an innovative company dedicated to the in-house discovery and development of novel drugs that address global unmet medical needs. Our R&D team is led by global top-notch scientists and specialists. Leveraging our research and development capabilities and efficient operations, we have built an internally-developed product portfolio with a diverse yet synergistic suite of four major therapeutic areas, namely ophthalmic drugs, recombinant botulinum toxin, immuno-oncology drugs and pet immune drugs. Our product pipelines include a number of first-in-class drug candidates, and our major products are about to commercialization.